# Lixia Diao

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lixia-diao/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,370 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 72 |
| i10-index | 152 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5089771018 |
| ORCID iD | https://orcid.org/0000-0001-6995-4492 |
| Works | 605 |

## Researcher papers

Showing 12 of 14.

- [An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance](https://scholariq.org/papers/an-epithelial-mesenchymal-transition-gene-signature-predicts-resistance-to-egfr/)
- [Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression](https://scholariq.org/papers/metastasis-is-regulated-via-microrna-200-zeb1-axis-control-of-tumour-cell-pd-l1/)
- [Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities](https://scholariq.org/papers/patterns-of-transcription-factor-programs-and-immune-pathway-activation-define/)
- [Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities](https://scholariq.org/papers/co-occurring-genomic-alterations-define-major-subsets-of-i-kras-i-mutant-lung/)
- [Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer](https://scholariq.org/papers/targeting-dna-damage-response-promotes-antitumor-immunity-through-sting-mediated/)
- [STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment](https://scholariq.org/papers/stk11-lkb1-deficiency-promotes-neutrophil-recruitment-and-proinflammatory/)
- [A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition](https://scholariq.org/papers/a-patient-derived-pan-cancer-emt-signature-identifies-global-molecular/)
- [Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1](https://scholariq.org/papers/proteomic-profiling-identifies-dysregulated-pathways-in-small-cell-lung-cancer/)
- [Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome](https://scholariq.org/papers/effect-of-kras-oncogene-substitutions-on-protein-behavior-implications-for/)
- [CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade](https://scholariq.org/papers/cd38-mediated-immunosuppression-as-a-mechanism-of-tumor-cell-escape-from-pd-1-pd/)
- [Structure-based classification predicts drug response in EGFR-mutant NSCLC](https://scholariq.org/papers/structure-based-classification-predicts-drug-response-in-egfr-mutant-nsclc/)
- [Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer](https://scholariq.org/papers/randomized-double-blind-phase-ii-study-of-temozolomide-in-combination-with/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Phagocytosis and Immune Regulation](https://scholariq.org/topics/phagocytosis-and-immune-regulation/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.